Central areolar choroidal dystrophy.

Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Ophthalmology (Impact Factor: 5.56). 03/2009; 116(4):771-82, 782.e1. DOI: 10.1016/j.ophtha.2008.12.019
Source: PubMed

ABSTRACT To describe the clinical characteristics, follow-up data and molecular genetic background in a large group of patients with central areolar choroidal dystrophy (CACD).
Retrospective case series study.
One hundred three patients with CACD from the Netherlands.
Ophthalmologic examination, including color vision testing, fundus photography, fluorescein angiography, fundus autofluorescence (FAF) imaging, optical coherence tomography, full-field electroretinography (ERG), multifocal ERG, and electrooculography. Blood samples were obtained for DNA extraction and subsequent analysis of the peripherin/RDS gene, as well as haplotype analysis.
Clinical characteristics, phenotypic range, clinical follow-up data, and FAF findings.
The mean age at onset of visual loss was 46 years, with subsequent gradual deterioration in visual acuity. Ninety-eight patients carried a p.Arg142Trp mutation in peripherin/RDS, whereas 5 affected members of a CACD family carried a p.Arg172Gln peripherin/RDS mutation. A remarkable variation in disease severity was observed, and nonpenetrance was seen up to the age of 64 years, in up to 21% of mutation carriers. However, most macular lesions in mutation carriers displayed a typical stage of CACD. Substantial changes were seen on FAF imaging after a mean follow-up period of 11 months. Electrophysiologic data were consistent with a central cone dystrophy. The age at onset and phenotypic characteristics of CACD show considerable overlap with atrophic age-related macular degeneration (AMD). The great majority of p.Arg142Trp-carrying CACD patients originated from the southeast region of the Netherlands, and haplotype analysis strongly suggested a common founder mutation.
When caused by a p.Arg142Trp mutation in the peripherin/RDS gene, CACD causes a central cone dystrophy phenotype. This mutation, which most likely originates from a common founder in most patients, is associated with a significant degree of nonpenetrance. In the elderly patient, CACD may be confused with AMD, especially in cases with decreased penetrance.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The A3243G point mutation in mitochondrial DNA (mtDNA) is associated with MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) and MIDD syndromes (maternally inherited diabetes and deafness). Both MELAS and MIDD patients can present with visual symptoms due to a retinopathy, sometimes before the genetic diagnosis is made.
    BMC Ophthalmology 06/2014; 14(1):77. · 1.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe the phenotypic and genotypic features in patients with PRPH2 mutations and negative electroretinograms. Retrospective observational case series. Records of patients with a confirmed molecular diagnosis of PRPH2 mutation, and an electronegative electroretinogram (reduced b-wave to a-wave amplitude ratio) under either photopic or scotopic conditions, were identified. Data examined included clinical history and retinal images, electrophysiology, and mutational analysis. Six patients were ascertained. All had presented with clinically evident maculopathy and Snellen visual acuities in the range of 6/6 to 1/60. All had negative electroretinograms in scotopic or photopic electroretinograms or both. Four patients were heterozygous for a previously reported missense mutation c.514C>T, p.R172W; 2 were heterozygous for the frame-shifting mutations c.259_266del8, p.D87fs and c.394delC, p.Q132fs. No other cause of electronegative electroretinogram was identified in any patient. Photopic On- and Off-response recording was useful in identifying On-pathway dysfunction. PRPH2 mutation can be associated with negative electroretinograms. This novel finding is not mutation specific and does not relate to the severity of the disease. The data add to the documented phenotypical variability of PRPH2 mutations and represent a further cause of negative electroretinogram.
    Retina (Philadelphia, Pa.) 03/2014; · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hereditary cone disorders (CDs) are characterized by defects of the cone photoreceptors or retinal pigment epithelium underlying the macula, and include achromatopsia (ACHM), cone dystrophy (COD), cone-rod dystrophy (CRD), color vision impairment, Stargardt disease (STGD) and other maculopathies. Forty-two genes have been implicated in non-syndromic inherited CDs. Mutations in the 5 genes implicated in ACHM explain ∼93% of the cases. On the contrary, only 21% of CRDs (17 genes) and 25% of CODs (8 genes) have been elucidated. The fact that the large majority of COD and CRD-associated genes are yet to be discovered hints towards the existence of unknown cone-specific or cone-sensitive processes. The ACHM-associated genes encode proteins that fulfill crucial roles in the cone phototransduction cascade, which is the most frequently compromised (10 genes) process in CDs. Another 7 CD-associated proteins are required for transport processes towards or through the connecting cilium. The remaining CD-associated proteins are involved in cell membrane morphogenesis and maintenance, synaptic transduction, and the retinoid cycle. Further novel genes are likely to be identified in the near future by combining large-scale DNA sequencing and transcriptomics technologies. For 31 of 42 CD-associated genes, mammalian models are available, 14 of which have successfully been used for gene augmentation studies. However, gene augmentation for CDs should ideally be developed in large mammalian models with cone-rich areas, which are currently available for only 11 CD genes. Future research will aim to elucidate the remaining causative genes, identify the molecular mechanisms of CD, and develop novel therapies aimed at preventing vision loss in individuals with CD in the future.
    Progress in Retinal and Eye Research 05/2014; · 9.44 Impact Factor